Results from these studies continue to come back with good news.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial
results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or
continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs);
continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable
results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical
studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
That's why, when Biogen shared initial positive
results from an early
study in December, the stock jumped 6 percent — and has
continued climbing, up 39 percent since Dec. 1, compared with a 19 percent gain for the Nasdaq biotechnology index.
This was expected based on the
results of the pregnancy outcome
study from which these women were selected, ie, women with exposure to fluoxetine late in pregnancy were more likely to have lower birth weight infants and were also more likely to breastfeed while
continuing to use the medication.
As America's obesity epidemic
continues to grow, a new
study from the University of Colorado Anschutz Medical Campus shows that a low - cost, non-profit weight loss program offers the kind of long - term
results that often elude dieters.
«The
results from the exenatide
studies justify
continued testing, but clinicians and patients are urged not to add exenatide to their regimens until more is known about their safety and impact on Parkinson's.»
Related sites Press release about the WISDOM steering committee's recommendation to
continue the
study The Medical Research Council More information about the WHI
study and the reasons it was stopped JAMA paper describing the
results from WISDOM
Patients with metastatic colorectal cancer (mCRC) that are mutation - free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit
from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first - line chemotherapy and an anti-EGFR monoclonal antibody, according to
study results (1) presented today at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain.
Our
results show that if these trends
continue, we can also expect to see substantially more cancers as a
result» *, said
study leader Dr Krishnan Bhaskaran, National Institute for Health Research Postdoctoral Fellow,
from the London School of Hygiene & Tropical Medicine, London, UK.
A
study that will be presented by Brendon Stiles, MD, Associate Professor of Cardiothoracic Surgery, Weill Cornell Medical College, New York - Presbyterian Hospital, at the 95th AATS Annual Meeting finds that these survivors still face
continued risks
resulting from recurrence of the original cancer, appearance of new primary cancers, or chronic pulmonary disease, and calls for long - term surveillance of these patients.
Related sites Press release about the decision to
continue WISDOM More information about the WHI
study and the reasons it was stopped JAMA paper describing the
results from WISDOM
While the materials
from the CFI subjects are extremely valuable and our
results are statistically significant, greater numbers of subjects must be analyzed to determine whether the correlations we detected
continue to hold up when more patients are
studied, and whether such correlations exist within people carrying other haplogroups.
Importantly, the survival curves for these groups did not begin to diverge until year 2 or beyond after initial surgery, and
continued to widen for the entire 10 - year period, which means preliminary
results from the relatively small DeCOG - SLT
study — with its 3 - year median follow - up [4]-- can not be relied upon to justify changing the standard of care away
from CLND.
Every time I encounter this opinion, I ask them where they gained that information and every single time it is
from the report on the news they heard, which
continues to circulate, which are undoubtedly a
result of Dangour's
study.
High intensity interval training (HIIT) has been
studied extensively and shows compelling fat - loss, fitness and health benefits for people ranging
from adolescents, athletes, weekend warriors, and those with health challenges.1, 2 A review of the literature shows us that: In healthy populations and athletes HIIT
results in similar, and perhaps greater improvements in...
Continue reading «How HIIT training can help you to lose fat and improve your health and fitness in (almost) no time at all!»
Studies suggest that as many as 1 in every 6 weddings in the US
results from couples meeting through on the internet...
Continue Reading →
The
study will draw on a range of evidence (for example, TEAM
results, surveys, and so on)
from teachers who have earned microcredentials for licensure advancement and compare their experiences with those of their peers who
continue to use more traditional models of professional development.
Promising
Results,
Continuing Challenges: National Assessment of Title I (1999) summarizes findings
from a variety of
studies conducted for the National Assessment of Title I, examining the implementation and impact of the program.
Despite the
continued negative
results from studies like Vanderbilt's, a growing number of Americans support merit pay for educators.
LOS ANGELES - Corrected
results from the J.D. Power and Associates» Initial Quality
Study show a
continued surge in quality by Japanese and European cars, especially for import brands with assembly plants in the United States.
Utilizing the
results of a comprehensive new
study of O'Neil base breakouts
from 1963 to 2017, Mike will analyze how many breakout stocks outperform in the short term versus how many
continue on to double, triple, or increase even more in price.
Each formula is the
result of years of
study, partnerships with veterinary schools and
continued input
from practicing veterinarians, breeders and our customers worldwide.
«The
results from the feline aging
study were remarkable,» Venator
continued.
Results from this
study will be used to apply further protections to the manatee and the seagrass meadows that they rely on, and encourage restoration work within the seagrass meadows, without which, they will
continue to decline.
Heat stress is projected to increase as a
result of both increased summer temperatures and humidity.55, 61 One
study projected an increase of between 166 and 2,217 excess deaths per year
from heat wave - related mortality in Chicago alone by 2081 - 2100.62 The lower number assumes a climate scenario with significant reductions in emissions of greenhouse gases (B1), while the upper number assumes a scenario under which emissions
continue to increase (A2).
The
results from a number of
studies that
continue to group the RF
from fossil fuel with that
from biomass burning are also shown.
The
study unleashed some disturbing
results, suggesting that roadside workers
continue to face danger
from distracted, speeding motorists.
Evidence linking psychological stress to asthma
continues to grow with our increased understanding of the natural history of asthma and the neurobiology underlying stress vulnerability.1 - 3 Stress exposure during infancy and early childhood may exert particularly robust effects on the physiological systems that respond to stress.4 - 6 Evidence
from animal and human
studies strongly suggests that early life adversity shapes stress neurobiology, 7
resulting in disturbed regulation of endocrine and autonomic processes (eg, hypothalamic - pituitary - adrenal [HPA] axis, sympathetic - adrenal - medullary system).
This finding is consistent with the
results of other
studies, 34 and many service providers are trying to find ways to encourage fathers to attend parenting programmes.35 Reports of difficulty sustaining behaviour change over time and the desire for further support have also been reported previously.9, 33
Continuing support to the group
from both volunteers and professionals has been proposed as well as flexible, open access, non-structured sources of support.37 Previous
studies have also suggested that 30 — 50 % of families who take part in parenting programmes are likely to show no benefit because of other events in their lives, and may therefore need more than a single intervention.36